Advertisement

Medicinal Chemistry Research

, Volume 27, Issue 2, pp 488–496 | Cite as

Design, synthesis and biological evaluation of 4-methoxy diaryl isophthalates as antiplatelet agents

  • Liu Xiu-jie
  • Wang Chao-qing
  • Meng Jie
  • Shi xin-xin
  • Yan ya-nan
  • Liu Xu-guang
Original Research
  • 326 Downloads

Abstract

A series of 4-methoxy diphenyl isophthalates, which are the isosturctural analogs of picotamide, were designed and synthesized using the concept of isosterism. The structures of these new analogs were characterized by all means of spectroscopy, including 1H NMR, 13C NMR, and MS spectra. In vitro antiplatelet aggregation activities of these compounds were investigated by using Born’s test method. Among the 19 compounds tested for both ADP and collagen inducers, six of them (P216–P219 and P220–P221) were found to exhibit higher activity in vitro antiplatelet aggregation than Picotamide. In particular, the compound P220 bearing a nitrooxyl group showed the highest acitivity 72.1% (induced by collagen) and 72.5% (induced by ADP), with IC50 values of 0.30 μM/L induced by ADP (1.3 μM/L) and LD50 > 2500 mg/kg, could have dual mechanism of action. Evaluation of cytotoxic activity of the compounds against L929 cell line revealed that none of the compounds have significant cytotoxicity. Through the careful analysis of in vitro activity data, the SAR of these compounds was preliminarily deduced. The results of this study showed that 4-methoxy diaryl isophthalates derivatives are potential to become an antiplatelet aggregation agents.

Keywords

4-Methoxy diphenyl isophthalates Antiplatelet aggregation SAR, Organic synthesis 

Notes

Acknowledgements

The authors grate to the National Science Foundation of China (11341014) & the Committee of Science and Technology of Tianjin of China(15JCZDJC33100) for the financial supports and Shenyang Pharmaceutical University of China for running platelet aggregation assays.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. Abe S, Ochi H, Takahashi Y, Ishijima SA, Osumi M, Yamaguchi H (2000) Characteristic biological effects of itraconazole on L929 fibroblasts and their cell membrane. J Infect Chemother 6(1):35–40CrossRefPubMedGoogle Scholar
  2. Barbosa Jr F, Sertorio JT, Gerlach RF, Tanus-Santos JE (2006) Clinical evidence for lead-induced inhibition of nitric oxide formation. Arch Toxicol 80(12):811–816CrossRefPubMedGoogle Scholar
  3. Born GV (1962) Aggregation of blood platelets by adenosine diphosphate (ADP) and its reversal. Nature 194(4832):927–929CrossRefPubMedGoogle Scholar
  4. Brito FCF, Kummerle AE, Lugnier C, Fraga CAM, Barreiro EJ, Miranda ALP (2010) Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition. Eur J Pharmacol 638(1-3):5–12CrossRefPubMedGoogle Scholar
  5. Butwick AJ, Carvalho B (2010) Neuraxial anesthesia in obstetric patients receiving anticoagulant and antithrombotic drugs. Int J Obstet Anesth 19(2):193–201CrossRefPubMedGoogle Scholar
  6. Celestini A, Violi F (2007) A review of picotamide in the reduction of cardiovascular events in diabetic patients. Vasc Health Risk Manage 3(1):93–98Google Scholar
  7. Ellis JL, Augustyniak ME, Cochran ED, Earl RA, Garvey DS, Gordon LJ, Janero DR, Khanapure SP, Letts LG, Melim TJ, Murty MG, Schwalb DJ, Shumway MJ, Selig WM, Trocha AM, Young DV, Zemtseva IS (2005) NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflamm Pharmacol 12(5–6):521–534CrossRefGoogle Scholar
  8. Gresele P, Deckmyn H, Arnout J, Nenci GG, Vermylen J (1989) Characterization of N, N’-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Thromb Haemost 61(3):479–484PubMedGoogle Scholar
  9. Li GA, Wang X, Meng X, Lin YB, Li X, Liu XJ (2015) Design, synthesis of novel N,N’-bis-(halogenophenyl)-4-methoxybenzene-1,3-disulfonamides and evaluation of their anti-platelet aggregation activity. Acta Pharm Sin 50(2):185–190Google Scholar
  10. Liu XJ, He X, Shi CL, Meng J, Shao YL, Si HQ, Hu T (2011) Synthesis and in vitro activities on anti-platelet aggregation of N,N‛-di(2-substituted-phenyl)-4-methoxyisophthalamides and benzene-1,3-disulfonamides. Chin Chem Lett 22(10):1139–1142Google Scholar
  11. Liu XJ, Shi XX, Zhong YL, Liu N, Liu K (2012) Design, synthesis and in vitro activities on anti-platelet aggregation of 4-methoxybenzene-1,3-isophthalamides. Bioorg Med Chem Lett 22(21):6591–6595CrossRefPubMedGoogle Scholar
  12. Liu XJ, Wang SQ, Zhang J, Zhang J, Zhang FX, Li GZ, Wang BJ, Shao YL, Zhang LG, Fang L, Cheng MS (2006) Design, synthesis, and activities of novel derivatives of isophthalamide and benzene-1,3-disulfonamide. Chem Res Chin U 22(3):356–359CrossRefGoogle Scholar
  13. Mashayekhi V, Haj Mohammad ETK, Amidi S, Kobarfard F (2013) Synthesis of novel indole hydrazone derivatives and evaluation of their antiplatelet aggregation activity. Chem Pharm Bull 61(2):144–150CrossRefPubMedGoogle Scholar
  14. Meng J, Liu XJ, Shi CL (2011) Synthesis and anti-platelet aggregation activities of bis(4-substituted-phenyl)-4-methoxyisophthalates. J Chin Pharm Univ 21(3):195–198Google Scholar
  15. Nagy G, Clark, Joanna M, Buzás, Edit I, Gorman, Claire L, Cope AP (2006) Nitric oxide and inflammation. Inflamm Allergy Drug Targets 5(2):115–119CrossRefGoogle Scholar
  16. Reddy MVB, Tsai WJ, Qian K, Lee KH, Wu TS (2011) Structure–activity relationships of chalcone analogs as potential inhibitors of ADP-and collagen-induced platelet aggregation. Bioorg Med Chem 19(24):7711–7719CrossRefGoogle Scholar
  17. Sartori E, Camy F, Teulon JM, Caussade F, Virone-Oddos A, Cloarec A (1993) ChemInform abstract: synthesis and activities of new arylsulfonamido thromboxane A2 receptor antagonists. Cheminform 24(52):625–632Google Scholar
  18. Seymour RA, Williams FM, Oxley A, Ward A, Fearns M, Briqhan K, Rawlins MD, Jones PM (1984) A comparative study of the effects of aspirin and paracetamol (acetaminophen) on platelet aggregation and bleeding time. Eur J Clin Pharmacol 26(5):567–571CrossRefPubMedGoogle Scholar
  19. Violi F, Ghiselli A, Iuliano L, Pratico D, Alessandri C, Balsano F (1988) Inhibition by picotamide of thromboxane production in vitro and ex vivo. Eur J Clin Pharmacol 33(6):599CrossRefPubMedGoogle Scholar
  20. Xiong JW, Xiao H, Zhang ZX (2007) An experimental research on different detection conditions between MTT and CCK-8. Acta Laser Biol Sin 16(5):559–562Google Scholar
  21. Xu SY, Bian RL, Chen X (1991) Pharmacological experimental methods, 2rd ed. People’s medical Publishing House, Beijing, p 1438–1442Google Scholar
  22. Yip S, Benavente O (2011) Antiplatelet agents for stroke prevention. Neurotherapeutics 8(3):475–487CrossRefPubMedPubMedCentralGoogle Scholar
  23. Zhao DY, Jie M, Wang TT, Deng N, Liu XJ (2012) Synthesis and in vitro activities on anti-platelet aggregation of bis-phenyl-4-methoxyisophthalate compounds. J Chin Pharm Univ 43(1):21–24Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.The College of Chemistry and Chemical Engineering, Tianjin University of TechnologyTianjinChina
  2. 2.Tianjin Key Laboratory of Organic Solar Cells and Photochemical Conversion, School of Chemistry and Chemical Engineering Tianjin University of TechnologyTianjinChina

Personalised recommendations